Blueberry Therapeutics is a drug discovery and development company that focuses on modern drug delivery using nanopolymer technology. The company specializes in dermatology and nanomedicine, developing innovative therapies for common dermatological disorders.

Blueberry Therapeutics

Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feel better.

Blueberry focuses on the research and development of treatments for skin diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic.

In the clinic, Blueberry uses smart, agile, clinical designs to deliver high quality trials more rapidly and with reduced development costs. 

Blueberry will rapidly progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective and safe doses with full regulatory and ethical approval.

We have programs addressing Onychomycosis,  Tinea Pedis, Acne and Atopic Dermatitis.

SBRI Healthcare

Incline Equity Partners

Connecticut Skin Institute

Medical Incubator Japan

China Medical Venture Investment (HK) Limited

Catapult Ventures

GM&C Life Sciences Fund

NPIF Maven Equity Finance

Blueberry Therapeutics Ltd

Lovely to be invited back to Staffordshire University’s Careers event last Tuesday. A delight to speak to the students and share careers advice and as always, talk about science! 
#studentengagement #careersfair #science #biosciences

Delighted to be shortlisted for the Bionow awards for Company of the Year, a ‘by invitation only’ category. Thanks to the Bionow judges for shortlisting us after an incredible year, and congratulations to our fellow finalists! https://lnkd.in/e5ZMR-JZ

Blueberry Executives, John Ridden (CEO) and Mark Hollingworth (CFO), are in San Francisco this coming week to meet with industry leaders and investors at the #DermatologySummit (tomorrow, Sunday 7th) and @JPMorgan Healthcare Conference (8th to 11th). Be sure to connect with us if you are attending – we are keen to share our innovative approaches in dermatology and discuss investment and collaborative opportunities.

#BlueberryTherapeutics #Dermatology #DermatologySummit #JPMHC42

Today we are pleased to announce that BB2603, our novel topical terbinafine antifungal product, met primary and secondary endpoints in a Phase 2b trial (BBTAF202) in 111 patients with onychomycosis.

BB2603 was superior to placebo (vehicle), with a high level of statistical significance. These antifungal effects were achieved alongside an excellent safety profile.

You can learn more here: https://lnkd.in/esGvneQh

#dermatology #clinicaldata #drugdevelopment

We’d like to extend a warm welcome to our new Laboratory Technician, Megan Dawson. Megan joins us with a Masters in Medical Microbiology from The University of Manchester, having gained lots of relevant skills in an associate practitioner role at Alder Hey Children’s Hospital. In her spare time, Megan’s interests include attending festivals and gigs, and reading (she is a huge Harry Potter fan). Welcome to Blueberry, Megan!

BLUE

COM:BLUEBERRYTHERAPEUTICS

Blueberry Therapeutics